Core Viewpoint - The listing of Rebio Biotech (6938.HK) on the Hong Kong Stock Exchange marks a significant milestone for China's small nucleic acid drug development, transitioning from "technical accumulation" to "value realization" [1] Group 1: Market Reaction and Financial Performance - The market reacted positively, with Rebio's stock price rising over 29% in pre-listing trading and closing at 82.1 HKD per share on its first day, reflecting strong investor confidence in Chinese innovative pharmaceuticals [1] - Rebio's financial performance shows a strong revenue growth of 56.57% year-on-year, reaching 1.04 million RMB in the first half of 2025, while losses narrowed by 30.94% during the same period [4][5] - The revenue growth is primarily driven by licensing and collaboration agreements with major players like Boehringer Ingelheim and Qilu Pharmaceutical, indicating recognition of its underlying platform technology [4] Group 2: Strategic Development and R&D - Rebio's platform-based R&D approach is transforming the traditional investment model in biotechnology, moving from betting on single molecules to a modular and scalable development strategy [6] - The company aims to advance 2-4 assets to clinical trials annually, leveraging its platform's efficiency and confidence in its development capabilities [6] - Rebio has established a strong competitive barrier through its intellectual property, holding 255 granted patents and 218 pending applications, alongside a GMP-compliant production facility in Jiangsu [7] Group 3: Ecosystem and Global Strategy - Rebio's strategy combines internal development with external collaboration, targeting global diseases with significant patient populations, such as cardiovascular conditions [9] - The company has formed strategic partnerships, such as with Boehringer Ingelheim, to enhance its technology platform's recognition and optimize commercialization efficiency [11] - Establishing a clinical team in Sweden allows Rebio to conduct high-quality clinical trials independently, enhancing global development efficiency and regulatory communication [12] Group 4: Industry Implications - Rebio's listing signifies a shift in the Chinese biotechnology sector from "following innovation" to "source innovation," showcasing its platform-based R&D capabilities and global operational vision [13] - The company is positioned to accelerate its transition from clinical to commercial stages, with the potential for its platform value and pipeline to resonate in the emerging nucleic acid drug era [13]

Group 1 - The core viewpoint of the news is that Boya Bio's stock performance and financing activities indicate a mixed outlook, with significant financing activity but a decline in net profit year-over-year [1][2]. - On January 9, Boya Bio's stock rose by 0.82%, with a trading volume of 110 million yuan. The financing buy-in amount was 17.34 million yuan, while the financing repayment was 35.24 million yuan, resulting in a net financing outflow of 17.89 million yuan [1]. - As of January 9, the total balance of margin trading for Boya Bio was 685 million yuan, with a financing balance of 683 million yuan, accounting for 5.76% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of December 31, Boya Bio had 30,100 shareholders, a slight decrease of 0.03% from the previous period, while the average circulating shares per person increased by 0.03% to 16,737 shares [2]. - For the period from January to September 2025, Boya Bio reported a revenue of 1.474 billion yuan, representing a year-over-year growth of 18.38%. However, the net profit attributable to the parent company was 343 million yuan, reflecting a year-over-year decrease of 16.90% [2]. - Boya Bio has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 489 million yuan distributed over the past three years [3].

Market Overview - The A-share market is showing strong performance, with the Shanghai Composite Index surpassing 4100 points and trading volume exceeding 3 trillion [1] - The Hong Kong market is lagging, influenced by overseas events, particularly geopolitical tensions involving Iran and Mexico [1] - The U.S. Supreme Court's delay in ruling on tariffs is seen as a positive development for the market [1] Industry Insights - The commercial aerospace sector is highlighted as a strong investment theme, with China submitting applications for an additional 203,000 satellites, covering 14 satellite constellations [1] - The U.S. FCC has approved SpaceX's deployment of 7,500 second-generation satellites, indicating a competitive landscape in satellite technology [1] Company Developments - SanDisk has introduced a novel contract requiring full cash prepayment from clients to secure supply quotas for 1 to 3 years, benefiting the related supply chain [2] - New Sword Transmission, a key supplier for Tesla's humanoid robot, has initiated its IPO process, marking a significant milestone in the mass production of humanoid robots [2] Financial Highlights - WuXi Biologics reported a record high of 209 new projects signed in 2025, with a significant portion coming from the U.S. market [3] - The company has 945 ongoing projects, including 74 in Phase III clinical trials, which are expected to drive future revenue growth [3] - WuXi Biologics anticipates a 120%+ year-on-year revenue growth in 2025, with a total potential milestone payment of over $4 billion from collaborative projects [3] Technological Advancements - OpenAI has launched ChatGPT Health, integrating user medical records and health data to assist in understanding health reports and preparing for medical consultations [4] - The AI-assisted diagnostic services have been included in China's medical insurance framework, paving the way for more companies to apply for relevant certifications [5]

Core Insights - The global growth factor drug market is steadily increasing, projected to grow from 13.2 billion in 2018 to 15.9 billion by 2025, with a compound annual growth rate (CAGR) of 3.4% [8][9] - The Chinese growth factor drug market is recovering, expected to reach 7.1 billion by 2025, doubling from 2020 levels, driven by the introduction of more human-derived products and expanded indications [9][10] - The market is characterized by a diverse range of growth factor products, with FGF holding the largest market share, followed by EGF and NGF [10] Growth Factor Drug Industry Overview - Growth factors are bioactive substances that regulate cell proliferation, migration, survival, and differentiation during tissue repair by binding to specific receptors on cell membranes [2][3] - They operate through paracrine and endocrine mechanisms, influencing local and systemic physiological processes [2][6] Market Status - The global growth factor drug market is expected to exceed 20 billion by 2029, indicating a robust growth trajectory [8] - In China, the market experienced a decline from 2019 to 2020 due to concerns over non-human-derived products and stricter regulations, but is now on a recovery path [9][10] Product Approval Status - As of December 2025, 38 growth factor drugs are expected to be approved in China, with significant contributions from companies like Zhuhai Yisheng Biopharmaceutical and Beijing Shuanglu Pharmaceutical [10][11] Development Trends - The growth factor drug market is anticipated to grow due to increasing demand for treatments in open wound care, ophthalmic diseases, and nerve regeneration [11] - Expanding indications and supportive policies are expected to accelerate new drug development and approval processes [11]

Core Viewpoint - The newly launched Hong Kong Stock Connect Medical ETF by Huabao (159137) is expected to perform actively due to the rising interest in the medical sector and favorable market conditions, coinciding with a strong performance in both the Hong Kong and A-share medical sectors at the beginning of 2026 [1][2]. Group 1: ETF Launch and Market Context - The Hong Kong Stock Connect Medical ETF Huabao (159137) was established on December 31, 2025, and began trading on January 12, 2026 [2]. - The underlying index, the "CSI Hong Kong Stock Connect Medical Theme Index," has seen a 14.25% increase from January 1 to January 9, 2026, and a total annual increase of 48.20% in 2025, indicating a strong recovery in the Hong Kong medical sector [2][4]. - The ETF's launch coincides with a rare "sixteen consecutive days of gains" in the Shanghai Composite Index, reflecting heightened investor enthusiasm [1]. Group 2: Investment Strategy and Composition - The ETF covers four major sectors within the Hong Kong medical field: CXO, medical business and services, medical devices, and biopharmaceuticals, with over 80% of its weight concentrated in leading companies in CXO, internet healthcare, and high-end medical devices [2][4]. - The top ten constituents of the index include major players such as WuXi Biologics (15.28% weight), JD Health (11.84%), and Alibaba Health (5.42%), collectively accounting for 63.89% of the index [4]. Group 3: Market Potential and Valuation - The Hong Kong medical sector is characterized by significant growth potential, driven by an aging population and increasing healthcare demands, with the CXO market expected to grow at a CAGR of 26.56% from 2020 to 2025 [4]. - The index's valuation remains relatively low, with a TTM P/E ratio of 29.43, which is below historical averages, suggesting a favorable entry point for investors [5].

Group 1 - TSMC is progressing well with the development of its next-generation 1.4nm process, planning to start risk production in 2027 and gradually ramp up production in 2028. The company expects sales to reach NT$335 billion in December 2025, a year-on-year increase of 20.4%, slightly exceeding market expectations. Cumulative sales for 2025 are projected at NT$3.81 trillion, reflecting a year-on-year growth of 31.6% [2] - OpenAI is advancing audio AI technology and plans to release a more natural real-time voice model in 2026, aiming to replace screen interactions with voice. The company is also investing $1 billion with SoftBank Group in SB Energy to support its growth as a data center developer and operator [2] - Meta has reached agreements with nuclear power suppliers Oklo, Vistra, and TerraPower to potentially acquire up to 6.6 GW of nuclear power capacity by 2035, positioning itself as the largest nuclear energy buyer among tech giants to support its data center operations [2] - Merck is reportedly in talks to acquire cancer drug developer Revolution Medicines for between $28 billion and $32 billion, which would mark a significant transaction in the recent biotech merger wave and enhance its oncology product line [2] Group 2 - Geely Holding is likely to announce an expansion plan in the U.S. within the next 24 to 36 months, with brands like Zeekr and Lynk & Co potentially suitable for the U.S. market, aiming to accelerate its global layout and expand into high-end overseas markets [5] - BAIC New Energy has launched a pilot operation for the Arcfox Alpha S (L3 version) in collaboration with Beijing Mobility, with the first batch of vehicles expected to enter designated areas by Q2 2026, promoting the commercialization of autonomous driving technology [5] - China Resources Microelectronics has signed a strategic cooperation agreement with TCL Industries and Zhonghuan Lianxing, focusing on power devices, smart power modules, and MCUs to enhance competitiveness in the semiconductor supply chain [5] - Tencent's Chief AI Scientist stated that the company has a strong 2C gene and faces challenges in the 2B market in China, indicating a future exploration of differentiated development paths for 2B business [5] - Stone Technology has received approval from the CSRC for its Hong Kong IPO, planning to issue no more than 33.108 million shares, which will further expand its financing channels [6] Group 3 - Samsung Electronics' Galaxy S26 Ultra model will support eSIM and is expected to be released next month, while major tech companies like Google, Microsoft, and Meta are seeking memory supply support from Samsung and SK Hynix due to global memory shortages [11] - Toyota remains the top-selling car brand in Indonesia for 2025, while Tesla has surpassed Toyota in global market capitalization, reflecting ongoing market optimism for the electric vehicle sector and increasing pressure on traditional automakers [11] - Sumitomo Metal Mining is investing in a nickel wet processing plant in Indonesia to build a stable resource supply network, with Japan's nickel metal production expected to reach 106,000 tons by 2025 [11] - BMW Group expects global sales of 2.464 million units in 2025, a slight increase of 0.5% year-on-year, with a 12.5% decline in the Chinese market, while European and U.S. markets show growth of 7.3% and 5.0%, respectively [13] - LVMH is reportedly collaborating with Chinese beauty brand Mao Geping, although specific details of the partnership have not been disclosed, indicating its expansion in the beauty sector [13]

Core Insights - The article highlights the rapid growth and international recognition of the company, Yingen Biotech, which specializes in ADC (Antibody-Drug Conjugate) drug development since its establishment in 2019 [1] Group 1: Company Overview - Yingen Biotech has developed four leading technology platforms in the ADC field: DITAC (Immunotoxin Antibody Conjugate), DIBAC (Innovative Bispecific Antibody Conjugate), DIMAC (Immunomodulatory Antibody Conjugate), and DUPAC (Unique Payload Antibody Conjugate) [1] - The company has established a competitive ADC pipeline targeting various promising cancer markers, including HER2, B7-H3, HER3, TROP2, and B7-H4, as well as self-immune targets like BDCA2 [1] - Despite being a relatively new company, Yingen Biotech has secured licensing and strategic partnerships with well-known pharmaceutical companies, including BioNTech and GlaxoSmithKline, for several of its ADC pipelines [1] Group 2: Product Highlights - DB-1311 (B7-H3 ADC) shows significant potential in treating various cancers, particularly prostate cancer, and is closely following the clinical progress of Ifinatamab deruxtecan, which is currently in Phase III trials [2] - DB-1303 (HER2 ADC) aims to differentiate itself in the market by targeting both endometrial cancer (EC) and breast cancer (BC), with the potential to become the first HER2 ADC used for both high and low expression EC [2] - The global market for DB-1303 is promising, especially as it is one of the few ADCs progressing to Phase III clinical trials for HER2-Low BC, alongside DS-8201 [2] Group 3: Strategic Collaborations - Yingen Biotech has formed a strategic partnership with BioNTech, positioning itself within the emerging "second-generation IO+ADC" cancer treatment landscape, which is attracting interest from major multinational corporations [3] - The collaboration with BioNTech, which has also partnered with Bristol-Myers Squibb, enhances Yingen Biotech's global clinical development and commercialization capabilities, maximizing the potential value of its ADC pipeline [3]

投资者： 请问截止12月31日公司股东人数是多少？ 董秘： 您好，公司2025年12月31日股东人数及其详情请关注并查阅公司定期报告披露的相关内容，感 谢关注！ 投资者： 尊敬的董秘您好，贵公司2026年1月5日发布的解押公告披露的质押起始日期的质押在2023年 的公告中已解除，请问2026年1月5日发布的解押公告中解除的是否对应的是质押到期日为2028年5月17 日的质押记录？ 董秘： 您好，关于公司控股股东部分股份解除质押的事项已于2026年1月5日披露于证监会指定的信息 披露网站，详见《关于公司控股股东部分股份解除质押的公告》（2026-03），谢谢！ 投资者： 公司股票5年间从最高价（231元）算起，5年跌幅超90%。按照创业板有关规定，股票如果下 跌异常，要向投资者发布退市风险警示提醒。公司是否达到了退市风险警示的提示要求，还是会等到跌 到退市时才会发布退市风险警示公告呢？！ 董秘： 您好，公司严格按照法律法规履行信息披露义务。公司持续优化经营策略，加速推进自研产品 上市，强化市场宣传推广，促进公司稳健发展，谢谢！ 截至2026年1月9日收盘，智飞生物(300122)报收于19.8元，上涨1.69% ...

Group 1 - The article discusses the relationship between the net profit of YouRan Agriculture and the price of raw milk, indicating a significant correlation that impacts profitability [1][44]. - The analysis includes a detailed examination of how fluctuations in raw milk prices directly affect the financial performance of YouRan Agriculture, highlighting the importance of price stability for maintaining profit margins [1][44]. Group 2 - A deep report on Baipusais is scheduled, focusing on insights and analysis relevant to the pharmaceutical industry, which may reveal investment opportunities [2][8]. - The report will be presented by leading analysts in the pharmaceutical sector, emphasizing the importance of expert insights in navigating industry trends [2][8]. Group 3 - The article outlines a strategic focus on innovation within the pharmaceutical industry, projecting investment strategies leading up to 2026 [3][13]. - This strategy aims to identify key areas for growth and investment, reflecting the evolving landscape of the pharmaceutical market [3][13]. Group 4 - A comprehensive report on the military industry by Guokexun is set to provide in-depth analysis and insights, which could influence investment decisions in the defense sector [4][46]. - The report will be led by a military industry analyst, ensuring a thorough understanding of current trends and future prospects [4][46]. Group 5 - The article mentions a review and update of the industry allocation model, which is crucial for investors to understand market dynamics and make informed decisions [5][43]. - This session will provide insights into the performance of various sectors and how they align with investment strategies [5][43]. Group 6 - A report on the Sichuan-Chengyu region will be discussed, focusing on transportation and logistics, which are vital for regional economic development [6][26]. - The analysis will be presented by a transportation industry analyst, highlighting the significance of infrastructure in driving growth [6][26]. Group 7 - The article indicates a discussion on investment opportunities in the chemical industry leading up to 2026, suggesting potential areas for growth and development [7][32]. - This session will be led by prominent analysts in the chemical sector, providing valuable insights for investors [7][32]. Group 8 - An electronic industry perspective will be shared, focusing on current trends and future outlooks, which are essential for understanding market movements [8][47]. - The session will be conducted by leading analysts in the electronics field, ensuring a comprehensive overview of the industry [8][47].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 內幕消息 二零二六年度醫療健康大會簡報 本公告由WuXi Biologics (Cayman) Inc.藥明生物技術有限公司*（「本公司」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第 571章《證券及期貨條例》第XIVA部項下內幕消息條文（定義見上市規則）而作出。 本公司將於二零二六年一月十四日（美國太平洋時間）出席第44屆年度摩根大 通醫療健康大會（「年度醫療健康大會」），會上將進行包含本公司業務營運的 若干資訊的簡報（「簡報」）。為確保本公司所有股東及潛在投資者能夠公平及 時地取得該等信息，本公司於本公告納入簡報全文。本公司股東及潛在投資者 務請注意，簡報可能包含前瞻性陳述，該等陳述就其性質而言存在風險及不確 定性，簡報中陳述的任何估計及未來建議均基於若干假設及估計以及管理層 僅根據當前可得資料作出的判斷。 – 1 – 誠如簡報中所披露，本集團業務及財務表現依 ...